Progenics Pharmaceuticals (FRA:PGP) Long-Term Capital Lease Obligation : €13.42 Mil (As of Mar. 2020)

View and export this data going back to 1997. Start your Free Trial

What is Progenics Pharmaceuticals Long-Term Capital Lease Obligation?

Progenics Pharmaceuticals's Long-Term Capital Lease Obligation for the quarter that ended in Mar. 2020 was €13.42 Mil.

Progenics Pharmaceuticals's quarterly Long-Term Capital Lease Obligation declined from Sep. 2019 (€13.76 Mil) to Dec. 2019 (€13.51 Mil) and declined from Dec. 2019 (€13.51 Mil) to Mar. 2020 (€13.42 Mil).

Progenics Pharmaceuticals's annual Long-Term Capital Lease Obligation stayed the same from Dec. 2017 (€0.00 Mil) to Dec. 2018 (€0.00 Mil) but then increased from Dec. 2018 (€0.00 Mil) to Dec. 2019 (€13.51 Mil).

Progenics Pharmaceuticals Long-Term Capital Lease Obligation Historical Data

The historical data trend for Progenics Pharmaceuticals's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Progenics Pharmaceuticals Long-Term Capital Lease Obligation Chart

Progenics Pharmaceuticals Annual Data

Trend

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

13.51

Progenics Pharmaceuticals Quarterly Data
	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															13.09	13.55	13.76	13.51	13.42

Progenics Pharmaceuticals (FRA:PGP) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Progenics Pharmaceuticals Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Progenics Pharmaceuticals's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Progenics Pharmaceuticals (FRA:PGP) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Progenics Pharmaceuticals Inc (FRA:PGP) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

N/A

Address

One World Trade Center, Suite J, 47th Floor, New York, NY, USA, 10007

Website

http://www.progenics.com

Progenics Pharmaceuticals Inc is an oncology company focused on developing and commercializing targeted medicines and artificial intelligence to treat cancer. Its portfolio includes AZEDRA (to treat malignant and recurrent pheochromocytoma and paraganglioma); 1404 and PyL (imaging agents for prostate cancer); 1404 Index and PyL (analytical tools for analysis and indexing of images for prostate cancer); 1095 (treatment of metastatic prostate cancer); PSMA ADC (treatment of metastatic castration-resistant prostate cancer); and EXINI boneBSI (an analytical Bone Scan Index tool from bone scintigraphy images, currently sold in Europe and Japan). Its partnered products are RELISTOR (sold in the U.S., EU, Australia, and Canada) to treat opioid-induced constipation, and the PRO 140 HIV treatment.

Progenics Pharmaceuticals (FRA:PGP) Headlines

From GuruFocus

PGP Statement on SEC Settlement

By sperokesalga sperokesalga • 06-16-2023